Nimodipine oral solution - Arbor Pharmaceuticals

Drug Profile

Nimodipine oral solution - Arbor Pharmaceuticals

Alternative Names: AR 02; Nymalize

Latest Information Update: 16 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arbor Pharmaceuticals
  • Class Antihypertensives; Dihydropyridines
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • Marketed Subarachnoid haemorrhage

Most Recent Events

  • 16 Dec 2013 Launched for Subarachnoid haemorrhage in USA (PO) before 16 December 2013 - First global launch
  • 13 May 2013 Registered for Subarachnoid haemorrhage in USA (PO) - First global approval
  • 02 Dec 2011 AR 02 receives Fast Track designation for Undefined in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top